Literature DB >> 23952185

Treatment outcomes with lisdexamfetamine dimesylate in children who have attention-deficit/hyperactivity disorder with emotional control impairments.

Alain Katic1, Bryan Dirks, Thomas Babcock, Brian Scheckner, Ben Adeyi, Cynthia Richards, Robert L Findling.   

Abstract

OBJECTIVE: The purpose of this study was to assess lisdexamfetamine dimesylate (LDX) treatment effects based on baseline emotional control dysfunction in children with attention-deficit/hyperactivity disorder (ADHD) categorized with or without impairments of executive function (EF) emotional control.
METHODS: Post-hoc analyses of a 7 week, open-label LDX study in children with ADHD (American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision [DSM-IV-TR] defined) and impairments in EF control of emotional response. At baseline, participants were dichotomized by Behavior Rating Inventory of EF (BRIEF) emotional control domain T-scores of ≥65 (with impairment) or <65 (without impairment). ADHD Rating Scale-IV (ADHD-RS-IV), BRIEF Global Executive Composite and emotional control domain, Expression and Emotion Scale for Children (EESC) scores, Pearson correlations for BRIEF versus ADHD-RS-IV and EESC, and Clinical Global Impressions scores were assessed at baseline and end of study (week 7)/early termination (EOS/ET) by baseline category of BRIEF emotional control impairment. Safety assessments included treatment-emergent adverse events (TEAEs).
RESULTS: At baseline and EOS/ET, respectively, 53.0% and 20.7% met criteria for emotional control impairment. Participants with and without emotional control impairments had similar ADHD-RS-IV change scores. Mean (SD) change from baseline for those with and without emotional control impairments were -20.8 (12.89) and -14.6 (11.25) for BRIEF global scores and -16.0 (13.19) and -5.0 (9.48) for BRIEF emotional control domain scores. Participants with emotional control impairments had greater mean EESC total score changes. BRIEF emotional control domain and all ADHD-RS-IV scores indicated moderate correlations between change scores (all p<0.0001). Overall, 84.9% of participants had TEAEs (mostly mild-to-moderate in severity); 3.8% discontinued because of TEAEs.
CONCLUSIONS: The proportion of children with behavioral impairments in EF control of emotional response decreased during LDX treatment. ADHD symptoms improved in both groups. The moderate correlations between EF behaviors and ADHD symptoms suggest there may be utility in evaluating behavioral domains beyond core ADHD symptoms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23952185      PMCID: PMC3749705          DOI: 10.1089/cap.2012.0104

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  15 in total

1.  The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial.

Authors:  Ann C Childress; Valerie Arnold; Ben Adeyi; Bryan Dirks; Thomas Babcock; Brian Scheckner; Robert Lasser; Frank A Lopez
Journal:  J Atten Disord       Date:  2012-06-26       Impact factor: 3.256

2.  Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial.

Authors:  C Gillberg; H Melander; A L von Knorring; L O Janols; G Thernlund; B Hägglöf; L Eidevall-Wallin; P Gustafsson; S Kopp
Journal:  Arch Gen Psychiatry       Date:  1997-09

3.  Self-Regulation of Emotion, Functional Impairment, and Comorbidity Among ChildrenWith AD/HD.

Authors:  Arthur D Anastopoulos; Taylor F Smith; Melanie E Garrett; Erin Morrissey-Kane; Nicole K Schatz; Jennifer L Sommer; Scott H Kollins; Allison Ashley-Koch
Journal:  J Atten Disord       Date:  2010-08-04       Impact factor: 3.256

4.  A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders.

Authors:  J Biederman; S Faraone; S Milberger; J Guite; E Mick; L Chen; D Mennin; A Marrs; C Ouellette; P Moore; T Spencer; D Norman; T Wilens; I Kraus; J Perrin
Journal:  Arch Gen Psychiatry       Date:  1996-05

5.  Clinically relevant changes in emotional expression in children with ADHD treated with lisdexamfetamine dimesylate.

Authors:  Alain Katic; Lawrence Ginsberg; Rakesh Jain; Ben Adeyi; Bryan Dirks; Thomas Babcock; Brian Scheckner; Cynthia Richards; Robert Lasser; Atilla Turgay; Robert L Findling
Journal:  J Atten Disord       Date:  2010-12-20       Impact factor: 3.256

6.  Emotional lability in children and adolescents with attention deficit/hyperactivity disorder (ADHD): clinical correlates and familial prevalence.

Authors:  Esther Sobanski; Tobias Banaschewski; Philip Asherson; Jan Buitelaar; Wai Chen; Barbara Franke; Martin Holtmann; Bertram Krumm; Joseph Sergeant; Edmund Sonuga-Barke; Argyris Stringaris; Eric Taylor; Richard Anney; Richard P Ebstein; Michael Gill; Ana Miranda; Fernando Mulas; Robert D Oades; Herbert Roeyers; Aribert Rothenberger; Hans-Christoph Steinhausen; Stephen V Faraone
Journal:  J Child Psychol Psychiatry       Date:  2010-02-01       Impact factor: 8.982

7.  Behavior ratings of executive function among preschoolers with ADHD.

Authors:  E Mark Mahone; Jennifer Hoffman
Journal:  Clin Neuropsychol       Date:  2007-07       Impact factor: 3.535

8.  Emotional expression in children treated with ADHD medication: development of a new measure.

Authors:  Amy R Perwien; Christopher J Kratochvil; Douglas Faries; Brigette Vaughan; Joan Busner; Keith E Saylor; Curtis M Buermeyer; Stuart Kaplan; Ralph Swindle
Journal:  J Atten Disord       Date:  2008-01-11       Impact factor: 3.256

9.  Emotional expression during attention-deficit/hyperactivity disorders treatment: initial assessment of treatment effects.

Authors:  C J Kratochvil; D Faries; B Vaughan; A Perwien; J Busner; K Saylor; S Kaplan; C Buermeyer; R Swindle
Journal:  J Child Adolesc Psychopharmacol       Date:  2007-02       Impact factor: 2.576

10.  Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.

Authors:  Robert L Findling; Lawrence D Ginsberg; Rakesh Jain; Joseph Gao
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-12       Impact factor: 2.576

View more
  1 in total

1.  Immediate and Sustained Improvement in Behavior and Life Quality by Adenotonsillectomy in Children With Sleep-Disordered Breathing.

Authors:  Yung Jin Jeon; Jae-Jin Song; Jae-Cheul Ahn; Il Gyu Kong; Jae-Won Kim; Gyeong-Hun Park; Tae-Bin Won
Journal:  Clin Exp Otorhinolaryngol       Date:  2016-04-19       Impact factor: 3.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.